Cargando…

The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients

Detalles Bibliográficos
Autores principales:	Freitas, Marta, Capela, Tiago, Silva, Vítor Macedo, Xavier, Sofia, Magalhães, Joana Teixeira, Moura Marinho, Carla Maria, Cotter, José
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Thursday 23 June: NAFLD: Clinical aspects except therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252390/ http://dx.doi.org/10.1016/S0168-8278(22)00680-8

Ejemplares similares

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database
por: Tacke, Frank, et al.
Publicado: (2022)

Effects of SARS-CoV2 pandemic in a cohort of italian NAFLD patients
por: Stefanini, Bernardo, et al.
Publicado: (2022)

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study
por: Simão, André L., et al.
Publicado: (2022)

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses
por: Canha, Maria Ines, et al.
Publicado: (2022)

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease
por: Samer, Al-Dury, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine
por: Kulkarni, Anand, et al.
Publicado: (2022)

mRNA COVID-19 vaccine effectiveness in liver transplant patients
por: Khan, Muhammad, et al.
Publicado: (2022)

Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease
por: Mateu, Carlos Alventosa, et al.
Publicado: (2022)

The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19
por: Cohen, Jason, et al.
Publicado: (2022)

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
por: Younossi, Zobair, et al.
Publicado: (2022)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19
por: Lee, David Uihwan, et al.
Publicado: (2022)

The course of COVID-19 infection in patients with chronic hepatitis B and Delta
por: Parlar, Yavuz Emre, et al.
Publicado: (2022)

Evaluation of immune response and disease flares in metobolic-associated fatty liver disease patients following SARS-CoV-2 vaccination: a prospective cohort study
por: Shi, Junping, et al.
Publicado: (2022)

Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
por: Shen, Feng, et al.
Publicado: (2015)

Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic
por: Ayonrinde, Oyekoya, et al.
Publicado: (2022)

Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease
por: Schwimmer, J B, et al.
Publicado: (2013)

The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada
por: Janjua, Naveed, et al.
Publicado: (2022)

Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER)
por: Codoni, Greta, et al.
Publicado: (2022)

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program
por: Sypsa, Vana, et al.
Publicado: (2022)

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia
por: Gulbiani, Lasha, et al.
Publicado: (2022)

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022)

Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant
por: John, Binu, et al.
Publicado: (2022)

Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis
por: John, Binu, et al.
Publicado: (2022)

Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy
por: D’Ambrosio, Roberta, et al.
Publicado: (2022)

No effect of HBsAg positivity on antibody response after COVID-19 vaccine
por: Jargalsaikhan, Ganbolor, et al.
Publicado: (2022)

Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study
por: Iavarone, Massimo, et al.
Publicado: (2022)

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2022)

Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Post-COVID-19 cholangiopathy: does SARS-CoV-2 play a relevant role in histopathological findings?
por: de Almeida e Borges, Valéria Ferreira, et al.
Publicado: (2022)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.
por: Sempere, Elena Diago, et al.
Publicado: (2022)

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation
por: Nedumannil, Leya, et al.
Publicado: (2022)

Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis
por: Barreira, Ana, et al.
Publicado: (2022)

COVID-19 vaccine induced autoimmune hepatitis-a first case series from India
por: Iyengar, Sowmya, et al.
Publicado: (2022)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

Cholangiopathy after severe COVID-19: what do we know so far?
por: de Almeida e Borges, Valéria Ferreira, et al.
Publicado: (2022)

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study
por: Hunyady, Peter, et al.
Publicado: (2022)

Use of Tocilizumab in patients with stable chronic liver disease and severe COVID-19 for prevention of decompensated cirrhosis, a prospective, open-label, randomized controlled trial.
por: Rosales Renteria, Luis Alejandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ohvb1u3m10efrgm4g41599pml